Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 14 of 14 publications.
Skip to main content
von Scheele B, David K, Gaffney L, Niculescu L, Verburg KM. The total cost of treatment and the cost-effectiveness of valdecoxib vs diclofenac in the treatment of patients with osteoarthritis (OA) of the hip and/or knee. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):661.
Alten RH, von Scheele B, Gaffney L, Maciver F, Niculescu L. Cost-effectiveness of valdecoxib compared to diclofenac in patients with rheumatoid arthiritis (RA) in the United Kingdom (UK) and Germany. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6).
Schmidt RA, Ackerman SJ, Newstead GM, Quam JP, Mordin MM, Anastassopoulos K, Nishikawa RM. Comparative feature analysis of computed radiography for mammography (CRM) soft copy display vs. crm hard copy film: an observer performance study. Poster presented at the 90th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2004.
Eaton SC, Mangel AW, Hollis KA, Ameen VZ, Hamm LR, Andrews EB, Williams RL, Cook SF. Symptoms of diarrhea-predominant or alternating IBS: an exploratory analysis. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.
Hauber BHIV, Candrilli SD, Snyder EG, McBurney CR. Validation of a model to assess long-term disease progression in alzheimer's disease patients treated with rivastigmine. Poster presented at the 9th International Conference on Alzheimer's Disease and Related Disorders; July 2004.
Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004 May 4;140(9):689-99.
Finkelstein EA, Hicks KA. Obesity cost calculator for employers. Presented at the 2004 National Business Group on Health Founding Board Meeting; February 2004.
Mauskopf JA, Shih T, Baker T, Borker R, Stanford RH, Jhingran P. Budget impact analysis: combination fluticasone and salmeterol for asthma. Value Health. 2004 Jan 1;7(3):312.
Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.
Bahl R, Sinha A, Poulos C, Whittington D, Sazawal S, Kumar R, Mahalanabis D, Acosta CJ, Clemens JD, Bhan MK. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr. 2004 Jan 1;22(3):304-10.
Rothman KJ. A potential bias in safety evaluation during open-label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(5):295-8.
Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004 Jan 1;20(12):1883-93. doi: 10.1185/030079904X11510.
Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004 Jan 1;22(4):207-24.
Hauber B, Candrilli S, Snyder EH, McBurney CR. Validation of a model to assess long-term disease progression in Alzheimer's disease patients treated with rivastigmine. Neurobiol Aging. 2004 Jan 1;25:S136.